Exelixis Stock News & Updates
[WKN: 936718 | Symbol: EXEL]
Exelixis: Zanzalintinib as a Major Hope in Cancer Therapies Ahead of FDA Approval
Business Model: Exelixis focuses on targeted cancer therapies with kinase inhibitors. The main product,...
Exelixis: Zanzalintinib as a Great Hope in Cancer Therapies Before FDA Approval
Business model: Exelixis focuses on targeted cancer therapies with kinase inhibitors. The main product...
Exelixis - Oncology Specialist With Strong Pipeline, Positive Phase III Clinical Study Data for Zanzalintinib Opens Billion-Dollar Revenue Potential!
Business drivers: The US company Exelixis (EXEL) specializes in the development of active ingredients...
Wall Street Cautiously Treads Forward – oil Prices Decline – Defense Stocks in Focus, Novo Nordisk Ends Cooperation With Hims & Hers – Rezolve AI Included in the Russell 2000 – Tesla Launches the Robotaxi – Exelixis With Research Breakthrough – Fiserv With Stablecoin for the Masses - Meta Massively Ramps up in the AI Race – DAX Under Pressure After US Attack on Iran
The US stock markets are starting the week with slight gains, while crude oil prices are falling –...
Stocks in Action USA: Exelixis, Fiserv, Rezolve AI
Exelixis (EXEL) achieves breakthrough in colorectal cancer research with new drug combination! The...
Accumulation: Acadia Healthcare, ProSiebenSat.1, Exelixis, Nextracker and Advanced Drainage Systems.
Acadia Healthcare - Clinic operator benefits from rising patient numbers! Business driver: Acadia...
Stocks in Action USA: Oklo, Super Micro Computer and Exelixis.
Oklo (OKLO) - the energy start-up makes progress in building its first mini-nuclear power plant – site...
Wall Street Takes a Breather After the Tech Rally - Super Micro (+15%), AMD (+6%) and NVIDIA (+2.15%) are Riding the Saudi AI Wave. DAX (-0.60%) Stumbles After Record High - Rate Concerns and Sanctions Weigh on Europe's Markets!
After the wild roller coaster ride of the past weeks, Wall Street takes a breather – the S&P 500...
Exelixis: Following a 170% Profit Increase, Groundbreaking Study Results in Cancer Therapy are Published
With nearly 10 million deaths per year, cancer is one of the leading causes of death overall. Therefore,...
Exelixis poised for breakout to all-time high after strong numbers and new stock buyback program!
Exelixis impressed on February 11 with strong numbers for the fourth quarter, exceeding expectations...
- ‹
- 1
- ›